Advanced search
Publication Cover
Journal of Multidisciplinary Healthcare Volume 16, 2023 - Issue
Submit an article Journal homepage
288
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients

Yuhao Zeng1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Sha Zhu1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Zilin Wang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Junru Chen1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jindong Dai1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Zhenhua Liu1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Guangxi Sun1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jiayu Liang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Xingming Zhang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Zhipeng Wang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jinge Zhao1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2790-462XView further author information
ORCID Icon,
Yuchao Ni1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jiyu Yang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Minghao Wang1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Qiang Wei1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Xiang Li1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8471-0015View further author information
ORCID Icon,
Ni Chen2 Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Zhiping Li3 Department of Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Xin Wang3 Department of Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Yali Shen3 Department of Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jin Yao4 Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Rui Huang5 Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Jiyan Liu6 Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-4885-5481View further author information
ORCID Icon,
Diming Cai7 Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Hao Zeng1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1267-0509View further author information
ORCID Icon &
Pengfei Shen1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-0370-0411View further author information
ORCID Icon show all
Pages 503-513 | Received 21 Oct 2022, Accepted 17 Feb 2023, Published online: 23 Feb 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Kaelin W. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865–873. doi:10.1038/nrc2502
  • Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18(3):187–196. doi:10.1200/OP.21.00419
  • Bedke J, Gauler T, Grunwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179–188. doi:10.1007/s00345-016-1868-5
  • Zerdes I, Tolia M, Tsoukalas N, et al. Systemic therapy of metastatic renal cell carcinoma: review of the current literature. Urologia. 2019;86(1):3–8. doi:10.1177/0391560318802166
  • Rini B, Plimack E, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
  • Motzer R, Tannir N, McDermott D, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126
  • Motzer R, Jonasch E, Boyle S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. J Natl Compr Canc Netw. 2020;18(9):1160–1170. doi:10.6004/jnccn.2020.0043
  • Hahn AW, Klaassen Z, Agarwal N, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2019;2(6):708–715. doi:10.1016/j.euo.2019.09.002
  • Williamson S, Gill A, Argani P, et al. Report From the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44(7):e47–e65. doi:10.1097/PAS.0000000000001476
  • Zhu S, Chen J, Ni Y, et al. Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. Prostate. 2021;81(11):721–727. doi:10.1002/pros.24167
  • Sooriakumaran P, Dick JA, Thompson AC, Morley R. The central urology multidisciplinary team - is it time to change the referral criteria? An audit of practice in a district general hospital in London. Ann R Coll Surg Engl. 2009;91(8):700–702. doi:10.1308/003588409X12486167521190
  • Croke JM, El-Sayed S. Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature. Curr Oncol. 2012;19(4):e232–238. doi:10.3747/co.19.944
  • Kočo L, Weekenstroo H, Lambregts D, et al. The effects of multidisciplinary team meetings on clinical practice for colorectal, lung, prostate and breast cancer: a systematic review. Cancers. 2021;13(16):4159. doi:10.3390/cancers13164159
  • Betschart P, Babst C, Schmid S, et al. Shared decision-making for patients with advanced urological malignancies: evaluation of a joint urological-oncological clinic model. Oncol Res Treat. 2019;42(7–8):366–374. doi:10.1159/000499721
  • Rao K, Manya K, Azad A, et al. Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int. 2014;114(Suppl 1):50–54. doi:10.1111/bju.12764
  • Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy. 2015;119(4):464–474. doi:10.1016/j.healthpol.2014.09.006
  • Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72. doi:10.1016/j.ctrv.2015.11.007
  • Xiang Y-Y, Deng C-C, Liu H-Y, Kuo Z-C, Zhang C-H, He Y-L. The prognostic effect of multidisciplinary team intervention in patients with advanced gastric cancer. Curr Oncol. 2022;29(2):1201–1212. doi:10.3390/curroncol29020102
  • De Ieso PB, Coward JI, Letsa I, et al. A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. Br J Cancer. 2013;109(9):2295–2300. doi:10.1038/bjc.2013.586
  • Syn NL, Yong WP, Goh BC, Lee SC. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin Drug Metab Toxicol. 2016;12(8):911–922. doi:10.1080/17425255.2016.1196187
  • Taggar AS, Martell K, Husain S, Peacock M, Sia M, Gotto G. Exposure to radiation and medical oncology training: a survey of Canadian urology residents and fellows. Can Urol Assoc J. 2018;12(10):321–325. doi:10.5489/cuaj.5147

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.